Nickols G A, Nickols M A, Helwig J J
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston 77550.
Endocrinology. 1990 Feb;126(2):721-7. doi: 10.1210/endo-126-2-721.
The humoral hypercalcemia of malignancy factor (also called PTH-related protein or PTHrp) has been shown to produce effects similar to PTH in the kidney, bone, and cardiovascular system. Binding of PTHrp and PTH has been characterized in renal and osseous tissues, but not in vascular tissue. We have attempted to characterize the interaction of both human PTHrp and rat PTH to renal microvessels as a model of vascular smooth muscle and in a renal tubule preparation from the same rabbit kidneys. Previous studies have shown the microvessel and tubule preparations to be distinct based upon morphological examination, differential enzyme markers, calcitonin and vasopressin-sensitive adenylate cyclase distribution, and different characteristics of guanine nucleotide and of oxidized PTH activation of the adenylate cyclases associated with the preparations. Human PTHrp and rat PTH were iodinated by standard techniques and purified by HPLC. Both ligands bound to microvessels and tubules in a saturable, specific manner, Maximal specific binding of either ligand was 65-75% in microvessels and 80-90% in renal tubules. The time courses of binding of both ligands were identical with steady state achieved within 20 min in the smooth muscle of microvessels and 15 min in the tubules at 22 C. In equilibrium competition binding experiments, bound 125I-PTHrp was displaced by both PTHrp and PTH in microvessels and tubules. Rat PTH displayed slightly higher affinity in microvessels and tubules than PTHrp. Identical results were obtained with 125I-PTH as ligand. Specificity of binding of PTHrp and PTH to both microvessels and tubules was excellent, with competition observed between the radioactive ligand and bovine and rat PTH, PTHrp, and the antagonists, [Nle8,18, Tyr34]bovine PTH and [Nle8,18, Tyr34]bovine PTH but not with several other peptides of unrelated structure. The only major difference in binding between microvessels and tubules was a smaller number of binding sites in microvessels compared to tubules. These results indicate that vascular tissue contains receptor sites for PTH and PTHrp as identified by radioligand binding techniques. These receptors are similar in characteristics to the receptors of renal tubular tissue. Both PTH and PTHrp appear to interact with the receptors of rabbit kidney microvessels and tubules.
恶性肿瘤体液性高钙血症因子(也称为甲状旁腺激素相关蛋白或PTHrp)已被证明在肾脏、骨骼和心血管系统中产生与甲状旁腺激素(PTH)相似的作用。PTHrp和PTH在肾脏和骨组织中的结合特性已得到表征,但在血管组织中尚未明确。我们试图以兔肾微血管作为血管平滑肌模型,并在来自同一兔肾的肾小管制剂中,表征人PTHrp和大鼠PTH的相互作用。先前的研究表明,基于形态学检查、差异酶标记、降钙素和血管加压素敏感的腺苷酸环化酶分布以及与制剂相关的鸟嘌呤核苷酸和氧化型PTH对腺苷酸环化酶激活的不同特性,微血管和肾小管制剂是不同的。人PTHrp和大鼠PTH通过标准技术进行碘化,并通过高效液相色谱法纯化。两种配体均以饱和、特异性方式与微血管和肾小管结合。任一配体的最大特异性结合在微血管中为65 - 75%,在肾小管中为80 - 90%。在22℃下,两种配体的结合时间进程相同,微血管平滑肌在20分钟内达到稳态,肾小管在15分钟内达到稳态。在平衡竞争结合实验中,微血管和肾小管中的125I - PTHrp均被PTHrp和PTH取代。大鼠PTH在微血管和肾小管中的亲和力略高于PTHrp。以125I - PTH作为配体也获得了相同的结果。PTHrp和PTH与微血管和肾小管的结合特异性良好,放射性配体与牛和大鼠的PTH、PTHrp以及拮抗剂[Nle8,18, Tyr34]牛PTH和[Nle8,18, Tyr34]牛PTH之间存在竞争,但与其他几种结构不相关的肽不存在竞争。微血管和肾小管结合的唯一主要差异是微血管中的结合位点数量比肾小管少。这些结果表明,通过放射性配体结合技术确定,血管组织含有PTH和PTHrp的受体位点。这些受体在特性上与肾小管组织的受体相似。PTH和PTHrp似乎都与兔肾微血管和肾小管的受体相互作用。